Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
05/2000
05/31/2000EP1003525A1 Composition and method for regulating cell proliferation and cell death
05/31/2000EP1003523A1 Method of treatment of liver tumours and pharmaceutical compositions for use therein
05/31/2000EP1003516A1 Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
05/31/2000EP1003510A1 Method for treating headache pain with topical local anesthetic compositions
05/31/2000EP1003507A1 Combination therapy comprising amlodipine and a statin compound
05/31/2000EP1003503A1 Therapeutic combinations comprising amlodipin and atorvastatin
05/31/2000EP1003499A1 Diclofenac solution for topical application
05/31/2000EP1003490A1 Transdermal therapeutic system (tts) for administering sexual steroid hormones
05/31/2000EP1003489A1 Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic and pruritic conditions therewith
05/31/2000EP1003486A2 Pharmaceutical compositions containing an effervescent acid-base couple
05/31/2000EP1003485A1 Micro-osmotic controlled drug delivery systems
05/31/2000EP1003484A1 Improved multiparticulate tablet with quick disintegration
05/31/2000EP1003483A1 Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity
05/31/2000EP1003481A1 Fibrinogen-coated microspheres
05/31/2000EP1003480A1 Conjugated peptide nucleic acids having enhanced cellular uptake
05/31/2000EP1003477A2 Therapeutical system for transdermal delivery of levonorgestrel
05/31/2000EP1003476A1 Prolonged release active agent dosage form adapted for gastric retention
05/31/2000EP1003474A1 Method of treating dry eye disease with purinergic receptor agonists
05/31/2000EP1003370A1 Method of enhancing magnesium absorption and prevention of atherosclerosis
05/31/2000EP0721326B1 Contraceptive compositions
05/31/2000EP0635016B1 Benzodiazepine derivatives and protein and polypeptide conjugates thereof
05/31/2000EP0521880B2 Contrast medium containing a non-ionic contrast agent and sodium and calcium salts
05/31/2000CN1255163A Compounds
05/31/2000CN1255065A Medicinal preparation containing lipophilicity inert gas
05/31/2000CN1255057A Aqueous pharmaceutical composition comprising active ingredient which is highly insoluble in water
05/31/2000CN1255053A Ascorbyl-phosphoryl-cholesterol
05/31/2000CN1254558A S-(3-hydroxypropyl)-L-cysteine composition as oral medicine
05/31/2000CN1052878C Buffer choline phosphorus aqueous solution and its preparation method, medicine and usage
05/31/2000CN1052877C Ranitidine compositions
05/30/2000US6069301 Antibodies which bind to insect gut proteins and their use
05/30/2000US6069140 Pharmaceutical compositions comprising texaphyrins
05/30/2000US6069137 Administering oligosaccharide
05/30/2000US6069135 Use of hyaluronic acid or its derivatives to enhance delivery of therapeutic agents
05/30/2000US6069133 Targeted delivery of genes encoding interferon
05/30/2000US6068999 Dietary supplement for supporting cerebrovascular tone and treating migraine headaches
05/30/2000US6068860 For topical administration comprising foscarnet and an antiinflammatory glucocorticoid, with a carrier based on galactolipids comprising digalactosyldiacylglycerols, and a polar solvent; treating herpes infections
05/30/2000US6068859 Controlled-release dosage forms of Azithromycin
05/30/2000US6068855 Mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixer so as to form an agglomerates, extruding the agglomerate to form an extrudate
05/30/2000US6068851 Formulation for use in the prevention of pathogen induced diseases including HIV and HSV
05/30/2000US6068850 A stable aqueous formulation of a peptide related compound comprising atleast one peptide compoun and water, wherein the formulation is stable at 37 degree c. atleast 2 months, useful in an implantable drug delivery device
05/30/2000CA2171844C Sustained release formulations for 24 hour release of metoprolol
05/30/2000CA2159326C Method for treating amyloidosis
05/30/2000CA2144407C Biodegradable polymer matrices for sustained delivery of local anesthetic agents
05/30/2000CA2083333C High dosage topical forms of collagenase
05/30/2000CA2050067C Controlled drug release composition
05/30/2000CA2002472C Liquid oral formulation
05/25/2000WO2000029620A1 Methods of facilitating vascular growth
05/25/2000WO2000029601A1 A method for depopulating of vertebrate testis and for generation of transgenic species
05/25/2000WO2000029600A1 Systemic viral/ligand gene delivery system and gene therapy
05/25/2000WO2000029555A1 Methods using genetic package display for detecting and identifying protein-protein interactions
05/25/2000WO2000029481A1 Anionic-cationic polyion complexes comprising zwitterionic monomer component
05/25/2000WO2000029477A1 Poly(alpha-1,4-d-glucan) and thermoplastic polymer mixtures containing the same
05/25/2000WO2000029449A1 Biopolymer salts with low endotoxin levels, biopolymer compositions thereof and methods of making the same
05/25/2000WO2000029427A2 Antennapedia homeodomain helix 3 derived translocation vectors
05/25/2000WO2000029205A1 Apparatus and method for manufacturing moulded products
05/25/2000WO2000029103A1 Method and apparatus for liposome production
05/25/2000WO2000029029A1 Compositions and methods for producing vascular occlusion
05/25/2000WO2000029028A1 Pharmaceutical conjugates of glycoproteins and insoluble carriers
05/25/2000WO2000029027A1 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
05/25/2000WO2000029026A1 Suppositories
05/25/2000WO2000029025A1 Stable amorphous amifostine compositions and methods for the preparation and use of same
05/25/2000WO2000029024A1 Formulation of adenovirus for gene therapy
05/25/2000WO2000029021A1 Percutaneously administrable preparations containing cerebral function activators
05/25/2000WO2000029013A1 Stable aqueous insulin preparations without phenol and cresol
05/25/2000WO2000029008A2 Hiv-specific t-cell induction
05/25/2000WO2000028998A1 Liquid ophthalmic preparations
05/25/2000WO2000028994A1 Copolymer compositions for treating viral infections
05/25/2000WO2000028990A1 Pharmaceutical composition for modified release insulin sensitiser
05/25/2000WO2000028989A1 Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
05/25/2000WO2000028979A1 Dry powder for inhalation
05/25/2000WO2000028973A1 Process for preparing oral calcium compositions
05/25/2000WO2000028972A2 Nanocapsules and method of production thereof
05/25/2000WO2000028970A1 Vaginally administrable progesterone-containing tablets and method for preparing same
05/25/2000WO2000028969A2 Methods for preparing coated drug particles and pharmaceutical formulations thereof
05/25/2000WO2000028967A1 Drug delivery device, especially for the delivery of androgens
05/25/2000WO2000028952A1 Flavour blend for masking unpleasant taste of zinc compounds
05/25/2000WO2000028942A1 Process for the manufacture of liquid filled capsules
05/25/2000WO2000028821A1 Therapeutic anti-fungal nail preparation
05/25/2000WO2000018254A3 Method of protecting heat- or oxygen-labile compounds to preserve activity and bioavailability
05/25/2000WO2000007603A9 End modified thermal responsive hydrogels
05/25/2000WO2000002576A9 Egf-genistein for prevention of restenosis
05/25/2000DE19854139A1 Antiprotozoal composition useful for e.g. treating malaria and sleeping sickness comprises diminazene diaceturate, glycerol and N-methylpyrrolidone
05/25/2000DE19853985A1 Producing solid dosage form, using molding calender of two cylinders with specific surface structures, avoids problems of misalignment of upper and lower halves of the product
05/25/2000DE19853832A1 Polyalkensäuren enthaltende Calcium-Phosphatzemente Polyalkenoic acids containing calcium phosphate cements
05/25/2000DE19853487A1 Use of dialkyl fumarate for treating transplant rejection and autoimmune disease
05/25/2000CA2352830A1 Biopolymer salts with low endotoxin levels, biopolymer compositions thereof and methods of making the same
05/25/2000CA2352463A1 Methods using genetic package display for detecting and identifying protein-protein interactions
05/25/2000CA2351711A1 Nanocapsules and method of production thereof
05/25/2000CA2351516A1 Copolymer compositions for treating viral infections
05/25/2000CA2351064A1 Drug delivery device, especially for the delivery of androgens
05/25/2000CA2351058A1 Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
05/25/2000CA2350919A1 Antennapedia homeodomain helix 3 derived translocation vectors
05/25/2000CA2350911A1 Hiv-specific t-cell induction
05/25/2000CA2350890A1 Aqueous compositions for long-term stable storage of adenovirus particles including uses and methods for preparing same
05/25/2000CA2350450A1 Flavour blend for masking unpleasant taste of zinc compounds
05/25/2000CA2349238A1 Systemic viral/ligand gene delivery system and gene therapy
05/25/2000CA2348781A1 Compositions and methods for producing vascular occlusion
05/25/2000CA2343946A1 Poly(alpha-1,4-d-glucan) and thermoplastic polymer mixtures containing the same
05/25/2000CA2340468A1 Methods of facilitating vascular growth
05/24/2000EP1002547A1 Hydrosoluble hedgehog protein in ionic complex and pharmaceutical use thereof
1 ... 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 ... 1712